Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation and emerging growth company, filed this Form 8-K on January 26, 2024. The report details a material definitive agreement entered into on the same date to secure financing for working capital purposes.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The primary financial metric disclosed is a new debt obligation:
- Principal Amount: $1,000,000
- Instrument: One-year convertible promissory note
- Interest Rate: 12.0% simple interest per annum
- Use of Proceeds: Working capital
Material Changes
The Company has incurred a new direct financial obligation of $1,000,000. This represents a material change in the Company's capital structure and liquidity position compared to the prior period, as it introduces a new debt instrument with equity conversion features.
Terms, Outlook, and Risks
Conversion Terms: The note includes a voluntary conversion right allowing the investor to convert the principal and accrued interest into common stock at a 10% discount to the 10-day volume-weighted average price (VWAP) determined immediately before January 26, 2024. Upon voluntary conversion, the investor receives warrants for 50% of the converted shares with an exercise price of 120% of the conversion price.
Mandatory Conversion: If the Company consummates a public offering prior to the note's maturity, the note and accrued interest will mandatorily convert into equity securities issued in that offering at the same price per share as other purchasers, subject to restricted securities status.
Regulatory Status: The securities were issued to an accredited investor under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, without public solicitation.
Investor Verification Checklist
- Verify the exact 10-day VWAP used to calculate the conversion price as of January 26, 2024.
- Review the full text of the Convertible Promissory Note Purchase Agreement (Exhibit 10.1) for prepayment penalties or additional covenants.
- Assess the potential dilution impact of the 50% warrant issuance upon voluntary conversion.
- Monitor for any upcoming public offerings that would trigger mandatory conversion of this debt.